image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 9 days, don't miss out!

Sigmaroc

October 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SRC
  • Price:
  • 58p
After a remarkable succession of “beats” SigmaRoc’s half-year update was in line and showed good momentum with revenues up 17% (13% like-for-like) at £290m and EBITDA increasing 15% to £55m. EBITDA margins were held at 19% (H1 ‘22: 19.4%) largely through price discipline. Revenues split 43:57 between industrial minerals and construction (of which 20% is residential) but profitability is higher in industrial minerals. By end March, it was a curate’s egg- good and bad in parts. Demand grew in the environment, agriculture and chemical segment and also metals. The pulp, paper & board segment was more subdued due to de-stocking in the paper industry at the start of the year. Infrastructure markets have continued to grow but residen ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author